Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7e2b9a11a3f71d165e7dd72230437a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f41ad3e3eb895fb77774c608c6e8eeb7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_add9617544c3ddfb82d5396a24b2fde6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ae1b6ebab679d5678ba939406b47331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d3df48906c75a2aac8ab56bcf52a673 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8df972d955839c938c95150486225137 |
publicationDate |
2021-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-112645932-A |
titleOfInvention |
Polymorph of EGFR inhibitor free base or acid salt thereof, preparation method and application thereof |
abstract |
The invention discloses a polymorphic form of an EGFR inhibitor free base or an acid salt thereof, a preparation method and application thereof. Specifically N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl) Polymorphic form of (methyl)amino)-4-methoxyphenyl)acryloylamide free base or acid salt thereof and preparation method thereof, and preparation of said polymorphic form in the treatment of EGFR mutant activity-mediated diseases The application in medicine is used to inhibit the activity of L858R EGFR mutant, T790M EGFR mutant and exon 19 deletion activating mutant, etc. It can be widely used in the prevention and treatment of cancer, especially non-small cell lung cancer and other related diseases, and is expected to be developed into A new generation of EGFR inhibitors. |
priorityDate |
2016-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |